Vivoryon's VIVA-MIND Phase IIa trial of varoglutamstat in early Alzheimer's disease failed to meet its primary and secondary endpoints, mirroring previous unsuccessful VIVIAD trial.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.